COLOGNE, Germany--(BUSINESS WIRE)--Leading AI language company DeepL has announced the results of a new survey, which explores the processes of AI translation and localization for global businesses.
A phase I and pharmacokinetic (PK) study of high dose selenomethionine (SLM) in combination with irinotecan (IRI) in patients with advanced solid tumors No significant financial relationships to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback